The US federal government has ordered another 1.4 million doses of Merck & Co and Ridgeback Biotherapeutics' oral antiviral molnupiravir for COVID-19, adding to an earlier agreement to
As expected, Merck & Co has moved ahead swiftly with an emergency use application for its oral antiviral molnupiravir, aiming to protect people with mild or moderate COVID-19 from devel
The AGILE programme, which is researching a second wave of COVID-19 therapies in the UK, has begun testing its first potential drug that researchers hope could alter the course of the pande
MSD and partner Moderna have started a late-stage trial of their personalised cancer vaccine V940 as a combination with MSD’s PD-1 inhibitor Keytruda for patients with non
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio